Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Cost of one month of treatment with

Published byBrittany Howard Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 1 Cost of one month of treatment with"— Presentation transcript:

1 Figure 1 Cost of one month of treatment with
the top 10 bestselling anticancer drugs in the USA and Norway Figure 1 | Cost of one month of treatment with the top 10 bestselling anticancer drugs in the USA10 and Norway130. Drug prices are calculated for an adult weighing 70 kg, with a body surface area of 1.7 m2. For drugs reimbursed through the Medicare part B programme, we obtained the average sales price (ASP) from the Centers for Medicare and Medicaid services131; for drugs reimbursed through Medicare part D, we obtained the 'full cost of the drug' (Ref. 132). Prasad, V. et al. (2017) The high price of anticancer drugs: origins, implications, barriers, solutions Nat. Rev. Clin. Oncol. doi: /nrclinonc

Download ppt "Figure 1 Cost of one month of treatment with"

Similar presentations

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,
Figure 1 Estimated annual percentages of new

Figure 1 Estimated annual percentages of new
Figure 6 Selected examples of TERS applications in material systems

Figure 6 Selected examples of TERS applications in material systems
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 3 Life expectancy at birth in all countries included

Figure 3 Life expectancy at birth in all countries included
Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.
Figure 2 Multiscale modelling in oncology

Figure 2 Multiscale modelling in oncology
Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Endocrinol. doi: /nrendo
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Copy-number variations in multiple myeloma

Figure 2 Copy-number variations in multiple myeloma

Similar presentations

Ads by Google